SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 7.8% Passive Stake in Zimmer Biomet Holdings Inc.

BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in Zimmer Biomet Holdings Inc. as of March 31, 2025, held for ordinary course of business purposes.

Summary

• BlackRock, Inc. filed an Amendment No. 10 to Schedule 13G regarding its beneficial ownership in ZIMMER BIOMET HOLDINGS INC.
• As of March 31, 2025, BlackRock, Inc. beneficially owned 15,573,187 shares of Zimmer Biomet Holdings Inc. Common Stock.
• This ownership represents 7.8% of the class of securities.
• BlackRock holds sole voting power over 14,050,398 shares and sole dispositive power over 15,573,187 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Various BlackRock subsidiaries and affiliates are involved in the beneficial ownership, with no single subsidiary holding more than 5% individually, except for entities marked with an asterisk in Exhibit 99, though none are explicitly marked in the provided text.

Sentiment

Score: 5

Explanation: The document is a neutral, routine regulatory filing disclosing beneficial ownership. It does not contain positive or negative news about the issuer's performance or outlook, nor does it indicate any change in investment strategy by the reporting entity beyond standard portfolio adjustments.

Positives

• The disclosure of a significant institutional stake by BlackRock, a major global asset manager, can signal confidence in Zimmer Biomet Holdings Inc. to other investors.
• The filing confirms that BlackRock's investment is passive, indicating no immediate intent to influence or change the control of Zimmer Biomet Holdings Inc.

Risks

• The document itself does not detail risks related to Zimmer Biomet Holdings Inc.'s operations or financial health, as it is a beneficial ownership filing by an investor.
• The primary risk related to this document is that it is a routine disclosure and does not provide new insights into the issuer's business or financial performance.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Zimmer Biomet Holdings Inc. or BlackRock, Inc. regarding the issuer's future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by BlackRock, Inc.)

Industry Context

This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., indicating its passive ownership stake in Zimmer Biomet Holdings Inc., a company in the medical device industry. Such disclosures are common for large asset managers that hold significant, but non-controlling, positions across numerous publicly traded companies as part of their investment strategies.

Comparison to Industry Standards

• This Schedule 13G filing by BlackRock, Inc. is a standard regulatory compliance document for institutional investors that acquire beneficial ownership of more than 5% of a class of a company's voting equity securities, indicating a passive investment intent.
• Large asset managers like BlackRock, Vanguard, and State Street routinely file Schedule 13G amendments to update their holdings in thousands of companies, including those in the healthcare and medical device sectors, such as Medtronic, Stryker, and Johnson & Johnson, reflecting their broad market index and active investment strategies.
• The 7.8% stake in Zimmer Biomet Holdings Inc. is consistent with the typical passive ownership percentages held by major institutional investors in large-cap companies, where stakes rarely exceed 10-15% without triggering more stringent reporting requirements or indicating an activist intent.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive investment stance by BlackRock, Inc.

Next Steps

• BlackRock, Inc. will continue to monitor its holdings in Zimmer Biomet Holdings Inc. and file further amendments to Schedule 13G as required by changes in its beneficial ownership percentage or investment intent.

Key Dates

Keywords

BlackRock, Zimmer Biomet Holdings Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment, SEC Filing, Ownership Disclosure